City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
The drug will be available in 600 hospitals and 105 DTPs
In clinical trials, treatment proved more effective than other therapies evaluated
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Subscribe To Our Newsletter & Stay Updated
